Skip to Content
How to talk to a doctor about advanced ovarian cancer >>

Megestrol Disease Interactions

There are 5 disease interactions with megestrol:

Major

Progestogens (Includes Megestrol) ↔ Thromboembolism

Severe Potential Hazard, High plausibility

Applies to: History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder, Cerebral Vascular Disorder

The use of progestogens, in general, is considered by manufacturers to be contraindicated in patients with active thrombophlebitis, cerebrovascular disease, or a current or past history of thromboembolic disorders. While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant. Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages. Whether or not this effect contributes to the development of thrombotic events is unknown. However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent. In addition, an increased risk of nonfatal venous thrombosis has been associated with oral contraceptive combinations containing desogestrel or gestodene relative to those that contain other progestins (e.g., levonorgestrel, norethindrone), suggesting some degree of hemostatic effect by progestogens.

References

  1. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991): 420-5
  3. "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho Pharmaceutical Corporation, Raritan, NJ.
View all 15 references
Moderate

Estrogens/Progestogens (Includes Megestrol) ↔ Fluid Retention

Moderate Potential Hazard, Moderate plausibility

Applies to: Congestive Heart Failure, Migraine, Seizures, Renal Dysfunction, Fluid Retention, Hypertension

Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid. In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.

References

  1. "Product Information. Estrace (estradiol)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Micronor (norethindrone)" Ortho McNeil Pharmaceutical, Raritan, NJ.
  3. "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho Pharmaceutical Corporation, Raritan, NJ.
View all 25 references
Moderate

Estrogens/Progestogens (Includes Megestrol) ↔ Retinal Thrombosis

Moderate Potential Hazard, Moderate plausibility

Applies to: Retinal Disorder, Visual Defect/Disturbance

Estrogens and progestogens may cause retinal thrombosis. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted. Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.

Moderate

Megestrol (Includes Megestrol) ↔ Diabetes Mellitus

Moderate Potential Hazard, High plausibility

Applies to: Diabetes Mellitus

Megestrol, like other progestational agents, can cause glucose intolerance. In addition, it may have glucocorticoid activity. New onset diabetes and exacerbation of preexisting diabetes have been reported in association with the chronic use of megestrol. Patients with diabetes mellitus should be monitored more closely during therapy with megestrol, and adjustments made accordingly in their antidiabetic regimen.

References

  1. Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51
  2. Henry K, Rathgaber S, Sullivan C, McCabe K "Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia." Ann Intern Med 116 (1992): 53-4
  3. Kilby JM, Tabereaux PB "Severe hyperglycemia in an HIV clinic: preexisting versus drug- associated diabetes mellitus." J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998): 46-50
View all 5 references
Moderate

Megestrol (Includes Megestrol) ↔ Hyperadrenocorticalism

Moderate Potential Hazard, High plausibility

Applies to: Adrenal Tumor, Hyperadrenocorticism

Megestrol appears to have glucocorticoid activity and may aggravate conditions of hyperadrenocorticalism. Clinical cases of overt Cushing's syndrome and adrenal insufficiency have been reported in association with the chronic use of megestrol.

References

  1. Leinung MC, Liporace R, Miller CH "Induction of adrenal suppression by megestrol acetate in patients with AIDS." Ann Intern Med 122 (1995): 843-5
  2. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  3. Caparros GC, Zambrana JL, Delgado-Fernandez M, Diez F "Megestrol-induced Cushing syndrome." Ann Pharmacother 35 (2001): 1208-10
View all 4 references

megestrol drug Interactions

There are 152 drug interactions with megestrol

megestrol alcohol/food Interactions

There is 1 alcohol/food interaction with megestrol

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide